Serum Institute of India is the vaccine producer that will invest 50 million pounds ($68.24 million) in Oxford Biomedica, one of the COVID-19 vaccine manufacturers for drug major AstraZeneca, the British cell therapy firm said.

• Signature Global Shares Soar 6% on Entering a Rs 1,283 Crore JV 
• Ashoka Buildcon Shares Slump 3% Despite Securing Rs 410 Crore Project 
• Zydus Lifesciences Gets USFDA Nod; Stock Trades Flat
• Religare Enterprises Shares Slumped 6% on Demerger Plan 
• Natco Pharma Gets CDSCO Nod; Shares Rally 12.5%

The proceeds of the transaction will be used to fund the development of the fallow area at Oxbox, the group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023.